Zacks Investment Research upgraded shares of Vapotherm (NYSE:VAPO) from a hold rating to a buy rating in a report published on Friday morning, Zacks.com reports. The brokerage currently has $18.00 price objective on the stock.
According to Zacks, “Vapotherm Inc. is a medical technology company. It designs and develops respiratory devices for the treatment of chronic lung and acute breathing disorders. The Company provides flow vapor transfer cartridges, delivery tubes and disinfection kits. Vapotherm Inc. is based in Exeter, New Hampshire. “
VAPO stock opened at $14.40 on Friday. Vapotherm has a one year low of $13.94 and a one year high of $24.63. The company has a current ratio of 5.22, a quick ratio of 5.34 and a debt-to-equity ratio of 1.42. The stock has a market capitalization of $254.61 million and a price-to-earnings ratio of -1.04. The firm’s 50-day moving average price is $19.78.
In related news, Director Anthony L. Arnerich acquired 10,000 shares of the stock in a transaction on Friday, August 2nd. The shares were acquired at an average price of $14.34 per share, for a total transaction of $143,400.00. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CEO Joseph Army acquired 15,000 shares of the stock in a transaction on Friday, August 2nd. The stock was bought at an average price of $14.28 per share, for a total transaction of $214,200.00. The disclosure for this purchase can be found here. 34.40% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in VAPO. American International Group Inc. purchased a new stake in Vapotherm in the 4th quarter worth approximately $61,000. New York State Common Retirement Fund purchased a new stake in Vapotherm in the 4th quarter worth approximately $118,000. Deutsche Bank AG purchased a new stake in Vapotherm in the 4th quarter worth approximately $121,000. Barclays PLC purchased a new stake in Vapotherm in the 4th quarter worth approximately $142,000. Finally, Marshall Wace North America L.P. purchased a new stake in Vapotherm in the 1st quarter worth approximately $161,000. Institutional investors and hedge funds own 47.13% of the company’s stock.
Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.
See Also: Are FAANG stocks a good investment?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.